WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
WuXi Biologics (WXXWY) has launched its Green CRDMO White Paper, showcasing the company's comprehensive sustainability initiatives in the biologics industry. The white paper details 242 energy-saving cases across five key scenarios, 12 energy systems, and 25 technology categories.
The company's sustainability efforts have gained significant recognition, including being featured in the UN Global Compact's "20 Case Examples for 20 Years" report as the only pharmaceutical industry case. In 2024, over 90% of WuXi Biologics' Kaizen projects achieved ESG benefits. The company has received multiple sustainability accolades, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices.
WuXi Biologics (WXXWY) ha pubblicato il suo White Paper Green CRDMO, illustrando le ampie iniziative di sostenibilità dell'azienda nel settore dei biologici. Il documento riporta 242 casi di risparmio energetico distribuiti su cinque scenari principali, 12 sistemi energetici e 25 categorie tecnologiche.
Gli sforzi di sostenibilità dell'azienda hanno ottenuto un importante riconoscimento, inclusa la citazione nel rapporto "20 Case Examples for 20 Years" del Global Compact delle Nazioni Unite come unico caso del settore farmaceutico. Nel 2024, oltre il 90% dei progetti Kaizen di WuXi Biologics ha generato benefici ESG. L'azienda ha inoltre ricevuto numerosi premi di sostenibilità, tra cui la valutazione MSCI AAA, la Medaglia Platinum di EcoVadis e l'inclusione nei Dow Jones Sustainability Indices.
WuXi Biologics (WXXWY) ha lanzado su White Paper Green CRDMO, mostrando las iniciativas integrales de sostenibilidad de la compañía en la industria de los biológicos. El documento detalla 242 casos de ahorro de energía en cinco escenarios clave, 12 sistemas energéticos y 25 categorías tecnológicas.
Los esfuerzos de sostenibilidad de la empresa han recibido un reconocimiento importante, incluida su aparición en el informe "20 Case Examples for 20 Years" del Pacto Mundial de la ONU como el único caso de la industria farmacéutica. En 2024, más del 90% de los proyectos Kaizen de WuXi Biologics lograron beneficios ESG. La compañía también ha obtenido múltiples galardones en sostenibilidad, como la calificación MSCI AAA, la Medalla Platino de EcoVadis y la inclusión en los Dow Jones Sustainability Indices.
우시 바이오로직스 (WXXWY)는 Green CRDMO 백서를 발간하여 바이오 의약품 분야에서의 포괄적인 지속가능성 활동을 소개했습니다. 백서에는 다섯 가지 주요 시나리오, 12개의 에너지 시스템, 25개의 기술 범주에 걸쳐 242건의 에너지 절감 사례가 상세히 수록되어 있습니다.
회사의 지속가능성 노력은 유엔 글로벌콤팩트의 "20 Case Examples for 20 Years" 보고서에 제약업계 유일 사례로 수록되는 등 큰 인정을 받았습니다. 2024년에는 우시 바이오로직스의 카이젠 프로젝트 중 90% 이상이 ESG 성과를 달성했습니다. 또한 MSCI AAA 등급, EcoVadis 플래티넘 메달, 다우존스 지속가능성 지수 포함 등 다수의 지속가능성 수상 실적을 보유하고 있습니다.
WuXi Biologics (WXXWY) a publié son livre blanc Green CRDMO, présentant les initiatives complètes de durabilité de l'entreprise dans le secteur des biologiques. Le document détaille 242 cas d'économie d'énergie répartis sur cinq scénarios clés, 12 systèmes énergétiques et 25 catégories technologiques.
Les efforts de durabilité de l'entreprise ont été largement reconnus, notamment par leur inclusion dans le rapport "20 Case Examples for 20 Years" du Pacte mondial des Nations unies en tant que seul cas de l'industrie pharmaceutique. En 2024, plus de 90% des projets Kaizen de WuXi Biologics ont apporté des bénéfices ESG. La société a également reçu plusieurs distinctions en matière de durabilité, dont la notation MSCI AAA, la médaille Platine d'EcoVadis et l'inclusion dans les Dow Jones Sustainability Indices.
WuXi Biologics (WXXWY) hat sein Green CRDMO White Paper veröffentlicht und damit die umfassenden Nachhaltigkeitsinitiativen des Unternehmens in der Biologika‑Branche vorgestellt. Das White Paper beschreibt 242 Energiesparfälle in fünf Schlüssel‑Szenarien, 12 Energiesystemen und 25 Technologiekategorien.
Die Nachhaltigkeitsmaßnahmen des Unternehmens erhielten beträchtliche Anerkennung, darunter die Nennung im UN Global Compact‑Bericht "20 Case Examples for 20 Years" als einziger Fall aus der Pharmaindustrie. Im Jahr 2024 erzielten über 90% der Kaizen‑Projekte von WuXi Biologics ESG‑Vorteile. Das Unternehmen erhielt zudem mehrere Nachhaltigkeitsauszeichnungen, darunter das MSCI‑Rating AAA, die EcoVadis Platinum‑Medaille und die Aufnahme in die Dow Jones Sustainability Indices.
- Featured as the only pharmaceutical case in UN Global Compact's '20 Case Examples for 20 Years' report
- Over 90% of 2024 Kaizen projects achieved ESG benefits
- Received multiple prestigious sustainability recognitions including MSCI AAA Rating and EcoVadis Platinum Medal
- New target matrix approved by Science Based Targets initiative (SBTi)
- None.
- End-to-end Green CRDMO solutions to enable global clients for broader positive impact
- Span from biologics research, development, manufacturing, and overall operations
- Integration with lean management and digitalization for continuous excellence
- A comprehensive ecosystem featuring diverse energy-saving and carbon-reduction initiatives
Along with an overall introduction to the company's strategic approach toward sustainability and climate change, the White Paper details WuXi Biologics' green innovation technologies across the research, development and manufacturing of biologics, and showcases the significant carbon reduction achieved through green operations. A total of 242 energy-saving cases are compiled in the White Paper, spanning five key energy-saving scenarios, 12 typical energy systems, and 25 technology categories within the industry.
In addition, the paper highlights how the integration of lean management and digitalization with sustainability enhances resource and energy efficiency, while driving continuous improvement. In 2024, over
With a deep understanding of the importance of tackling climate change, WuXi Biologics has adopted a comprehensive, integrated strategy with measurable targets and a well-defined roadmap. Recently, the company announced a new target matrix approved by SBTi, an acknowledgement that further inspires its steadfast dedication to leading the way to a net-zero economy.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are pleased to release the Green CRDMO White Paper with the aspiration that our insights and best practices will inspire and empower the whole industry to drive sustainable progress. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to deliver meaningful and far-reaching impacts."
As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-launches-green-crdmo-white-paper-to-advance-sustainability-in-biologics-industry-302550563.html
SOURCE WuXi Biologics
FAQ
What is WuXi Biologics' Green CRDMO White Paper and why is it significant?
How successful were WuXi Biologics' ESG initiatives in 2024?
What major sustainability recognitions has WuXi Biologics (WXXWY) received?
How many energy-saving cases does WuXi Biologics' White Paper include?
